Telisotuzumab vedotin (Teliso-V)
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Pepaxto · Melflu
Peptide-conjugated alkylator · approved 2021 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A peptide-conjugated alkylator that floods myeloma cells with melphalan — and its exposure rises as the kidney fails.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not a prominent trial signal; the renal relevance is pharmacokinetic and disease-context. A dedicated phase II study (BRIDGE) in myeloma patients with moderate or severe renal impairment characterized melphalan exposure across renal function and supported a reduced 30 mg dose for moderate impairment, with no new safety signals but substantial treatment-emergent toxicity (including deaths in a heavily pretreated population). As a melphalan-delivery system, its renal liabilities mirror the alkylator class (myelosuppression, and the alkylator-associated risk of tubular injury at high exposure).Source: Pour et al., Clin Lymphoma Myeloma Leuk 2026 (BRIDGE renal-impairment phase II)
Renal change, when it occurs, is typically subacute and multifactorial.
Distilled from: “Cytopenias within the first cycles; any renal change is typically subacute and multifactorial.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Lipophilic peptide-drug conjugate of melphalan. It diffuses readily into cells and is rapidly cleaved by aminopeptidases (markedly overexpressed in myeloma cells), releasing and trapping high intracellular concentrations of the alkylator melphalan — yielding roughly a 50-fold enrichment of payload versus free melphalan. With dexamethasone for relapsed/refractory multiple myeloma (regulatory status has shifted; included for onconephrology completeness).
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the Peptide-conjugated alkylator class.
Hematologic
Cytopenias, thrombosis, TMA
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 117 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
31 of 117 reports
Reported with hospitalization
29 of 117 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Melphalan flufenamide (melflufen) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Yondelis · Marine alkylating agent
Rhabdomyolysis → pigment nephropathy; hepatotoxicity.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Zanosar · Nitrosourea alkylator
Classic proximal tubular toxin → Fanconi and dose-limiting AKI.
Mithracin · Antitumor antibiotic
Cumulative tubular ATN; hypocalcemia is an on-target antiresorptive effect.
Ganite · Antineoplastic metal salt
Dose-limiting acute tubular necrosis; potentiated by dehydration and concurrent nephrotoxins.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.